Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q4 2021 Earnings Presentation
11 slides from Adc Therapeutics Sa's earnings presentation, Mar 3, 2022
Slide 1: 4Q 2021 / FY 2021 Earnings Call
4Q 2021 / FY 2021 Earnings Call March 3, 2022
Slide 2: Forward-looking statements
Forward-looking statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 3: Agenda
Agenda 01 Chris Martin Introduction Chief Executive Officer Jennifer Herron Commercial Highlights 02 Chief Commercial Officer Joseph Camardo Clinical Highlights 03 Chief Medical Officer Jenn Creel Financial Update 04 Chief Financial Officer 3
Slide 4: Recent Highlights
Recent Highlights - Net sales: $17M in 4Q and $34M in FY 2021 - driven by strong execution, differentiated product profile ZYNLONTA® - Marketing authorization application (MAA) validated by the European Medicines Agency (EMA) (loncastuximab tesirine-lpyl) - Focused ZYNLONTA development strategy to m
Slide 5: Positive ZYNLONTA Launch Dynamics
Positive ZYNLONTA Launch Dynamics Strong academic center support Broad patient access led to higher academic volume in 2021; through medical policies and community account volume increasing Advancing Patient Support program Broad Strong academic patient access center support Navigating COVID Key acc
Slide 6: Focused ZYNLONTA Strategy
Focused ZYNLONTA Strategy LOTIS-7 NHL LOTIS-6 § Phase 1 trial of ZYNLONTA in multiple combinations r/r FL § Expected initiation in 1H 2022 § Pivotal Ph 2 trial of ZYNLONTA monotherapy in r/r FL LOTIS-9 1L DLBCL § Voluntarily paused due to the withdrawal of idelalisib from unfit/frail the FL market;
Slide 7: Cami Pivotal Phase 2 trial in Hodgkin Lymphoma
Cami Pivotal Phase 2 trial in Hodgkin Lymphoma Novel ADC targeting CD25 and regulatory T cells (Tregs) § One-year follow-up complete § Abstract of topline results submitted to a medical meeting in 1H 2022; preparing for pre-BLA filing meeting § Interim data presented at ICML 2021 demonstrating encou
Slide 8: Solid Tumor Franchise: leveraging validated ADC Platform
Solid Tumor Franchise: leveraging validated ADC Platform Cami § Phase 1b trial of Cami + pembrolizumab protocol allows for small dose expansions if activity is seen, Targeting CD25 which was done at the 60 ug/kg dosing level. Dose escalation continuing. § Targeting advanced solid tumors with evidenc
Slide 9: 4Q and FY 2021 Financial Update (in $ millions)
4Q and FY 2021 Financial Update (in $ millions) Balance Sheet December 30, 2021 September 30, 2021 Cash and cash equivalents $466.5 $530.2 Statement of Cash Flows 4Q 2021 4Q 2020 FY 2021 FY 2020 Net cash used in operating activities $61.6 $51.7 $233.4 $168.7 Statement of Operations 4Q 2021 4Q 2020 F
Slide 10: Anticipated Development Milestones
Anticipated Development Milestones Hematology Programs ZYNLONTA: q 1H 2022: Initiate randomized portion of the LOTIS-5 confirmatory trial in combination with rituximab q 1H 2022: Initiate ZYNLONTA trial in multiple combinations in NHL q 2H 2022: Initiate LOTIS-9 trial of ZYNLONTA + rituximab in 1L u
Slide 11: 4Q 2021 / FY 2021 Earnings Call
4Q 2021 / FY 2021 Earnings Call